Market Overview

UPDATE: Cantor Fitzgerald Initiates Coverage on Bruker

Share:
Related BRKR
Benzinga's Top Downgrades
Cowen Downgrades Bruker To Market Perform
Related BRKR
Benzinga's Top Downgrades
Goldman Sachs Downgrades Bruker To Sell

According to a research report published Thursday, Cantor Fitzgerald has initiated Bruker (NASDAQ: BRKR) with a Buy rating and $16 PT.

In the report, Cantor Fitzgerald said, "Bruker has a highly diversified high-end scientific instrumentation portfolio targeting life science, applied, and industrial markets. In our view, the company is well positioned to capitalize on high-growth market segments over the next several years and deliver above-market top line growth, leveraging internal R&D and strategic tuckins. Additionally, with below sector average margins, Bruker has significant upside for margin expansion in the medium-term."

Bruker closed Wednesday at $13.39.

Latest Ratings for BRKR

DateFirmActionFromTo
Jan 2015Cowen & CompanyDowngradesOutperformMarket Perform
Dec 2014Goldman SachsDowngradesBuySell
Nov 2014Cantor FitzgeraldDowngradesBuyHold

View More Analyst Ratings for BRKR
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Initiation Analyst Ratings

 

Related Articles (BRKR)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Benzinga Professional